| Price | 8.75p on 07-11-2025 at 19:40:05 |
|---|---|
| Change | 0.00p 0% |
| Buy | 9.50p |
| Sell | 8.00p |
| Last Trade: | Sell 75,000.00 at 8.50p |
| Day's Volume: | 382,188 |
| Last Close: | 8.50p |
| Open: | 8.30p |
| ISIN: | GB00B02LCQ05 |
| Day's Range | 8.20p - 8.75p |
| 52wk Range: | 4.90p - 9.00p |
| Market Capitalisation: | £522.02m |
| VWAP: | 8.503882p |
| Shares in Issue: | 6.14b |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Allergy Thera. (AGY) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 75,000 | 8.50p | Uncrossing Trade |
16:35:24 - 07-Nov-25 |
| Sell* | 2,670 | 8.73p | Ordinary |
15:38:37 - 07-Nov-25 |
| Buy* | 299 | 8.77p | Ordinary |
14:01:47 - 07-Nov-25 |
| Buy* | 752 | 8.77p | Ordinary |
14:01:03 - 07-Nov-25 |
| Buy* | 1,094 | 8.77p | Ordinary |
14:00:14 - 07-Nov-25 |
| Sell* | 20,000 | 8.50p | Uncrossing Trade |
14:00:01 - 07-Nov-25 |
| Buy* | 1,094 | 8.77p | Ordinary |
13:59:08 - 07-Nov-25 |
| Unknown* | 234,375 | 8.5333p | Ordinary |
12:40:18 - 07-Nov-25 |
| Buy* | 5,000 | 9.00p | Ordinary |
12:27:29 - 07-Nov-25 |
| Buy* | 7,999 | 8.40p | Suspected BUY Trade |
11:00:25 - 07-Nov-25 |
Allergy Thera. (AGY) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 6th Nov 2025 7:22 am | RNS | Company to Evaluate Dual Listing on HKEX |
| 30th Oct 2025 7:00 am | RNS | G308 Phase III Year 2 Patient Screening Starts |
| 29th Oct 2025 7:00 am | RNS | Warrant Exercise and Paydown of Debt |
| 16th Oct 2025 7:00 am | RNS | Further progress in Phase I/IIa PROTECT trial |
| 31st Jul 2025 7:00 am | RNS-R | Grass MATA MPL Publications in Allergy Journal |
| 21st Jul 2025 7:00 am | RNS | Trading update for the year ended 30 June 2025 |
| 11th Jul 2025 7:00 am | RNS | PDMR Dealings |
| 13th Jun 2025 7:00 am | RNS-R | Allergy Therapeutics presents findings at EAACI |
| 10th Jun 2025 7:04 am | RNS-R | EAACI Early Career Research Award |
| 31st Mar 2025 7:00 am | RNS | Interim Results for six months ended 31 Dec 2024 |
